在RESONATE研究中，依鲁替尼用于治疗既往接受过治疗的伴有自身免疫性血细胞减少症的慢性淋巴细胞白血病患者。 - Suppr

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.

作者信息

Montillo M, O'Brien S, Tedeschi A, Byrd J C, Dearden C, Gill D, Brown J R, Barrientos J C, Mulligan S P, Furman R R, Cymbalista F, Plascencia C, Chang S, Hsu E, James D F, Hillmen P

机构信息

Niguarda Cancer Center, Milano, Italy.

MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Blood Cancer J. 2017 Feb 3;7(2):e524. doi: 10.1038/bcj.2017.5.

DOI:10.1038/bcj.2017.5

PMID:28157216

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5386339/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e1ec/5386339/3c8c9c8e9d28/bcj20175f1.jpg

相似文献

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.

Blood Cancer J. 2017 Feb 3;7(2):e524. doi: 10.1038/bcj.2017.5.

Chronic lymphocytic leukemia, autoimmune hemolytic anemia and ibrutinib: a case report and review of the literature.

Leuk Lymphoma. 2016;57(3):735-7. doi: 10.3109/10428194.2015.1071489. Epub 2015 Oct 12.

Rapid flare of immune thrombocytopenia after stopping ibrutinib in a patient with chronic lymphocytic leukemia.

Leuk Lymphoma. 2018 Jul;59(7):1738-1741. doi: 10.1080/10428194.2017.1387907. Epub 2017 Oct 30.

Response to ibrutinib of refractory life-threatening autoimmune hemolytic anemia occurring in a relapsed chronic lymphocytic leukemia patient with 17p deletion.

Leuk Lymphoma. 2016 Nov;57(11):2685-8. doi: 10.3109/10428194.2016.1154955. Epub 2016 Mar 21.

Rituximab therapy in a patient with autoimmune hemolytic anemia and immune thrombocytopenia associated with chronic lymphocytic leukemia.

Ann Saudi Med. 2008 Sep-Oct;28(5):382-5. doi: 10.5144/0256-4947.2008.382.

The use of ibrutinib in chronic lymphocytic leukemia.

Clin Adv Hematol Oncol. 2016 Mar;14(3):154-6.

Ibrutinib: searching for a partner drug.

Lancet Oncol. 2019 Jan;20(1):3-5. doi: 10.1016/S1470-2045(18)30861-1. Epub 2018 Dec 3.

Treatment of severe autoimmune hemolytic anemia in B-cell chronic lymphocytic leukemia with alemtuzumab.

Leukemia. 2007 Aug;21(8):1841-2; author reply 1842-3. doi: 10.1038/sj.leu.2404713. Epub 2007 Apr 26.

Obinutuzumab in the treatment of autoimmune haemolytic anaemia and immune thrombocytopenia in patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma.

Br J Haematol. 2021 Jan;192(1):e1-e4. doi: 10.1111/bjh.17105. Epub 2020 Oct 23.

Recurrence of autoimmune thrombocytopenia after treatment with fludarabine in a patient with chronic lymphocytic leukemia.

Leuk Lymphoma. 1994 Sep;15(1-2):187-8. doi: 10.3109/10428199409051696.

引用本文的文献

Evaluating rilzabrutinib in the treatment of immune thrombocytopenia.

Immunotherapy. 2025 Aug;17(11):767-782. doi: 10.1080/1750743X.2025.2545170. Epub 2025 Aug 11.

Efficacy and Safety Results With Rilzabrutinib, an Oral Bruton Tyrosine Kinase Inhibitor, in Patients With Immune Thrombocytopenia: Phase 2 Part B Study.

Am J Hematol. 2025 Mar;100(3):439-449. doi: 10.1002/ajh.27539. Epub 2025 Jan 22.

The Role of the Spleen and the Place of Splenectomy in Autoimmune Hemolytic Anemia-A Review of Current Knowledge.

Diagnostics (Basel). 2023 Sep 9;13(18):2891. doi: 10.3390/diagnostics13182891.

Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.

Leukemia. 2023 Jul;37(7):1464-1473. doi: 10.1038/s41375-023-01891-3. Epub 2023 May 18.

[Chinese guideline for the diagnosis and treatment of adult autoimmune hemolytic anemia (2023)].

Zhonghua Xue Ye Xue Za Zhi. 2023 Jan 14;44(1):12-18. doi: 10.3760/cma.j.issn.0253-2727.2023.01.003.

Targeted treatment of autoimmune cytopenias in primary immunodeficiencies.

Front Immunol. 2022 Aug 16;13:911385. doi: 10.3389/fimmu.2022.911385. eCollection 2022.

Ibrutinib as a treatment of hematologic autoimmune disorders in patients with indolent B-cell lymphoma.

Eur J Haematol. 2022 Dec;109(6):719-727. doi: 10.1111/ejh.13858. Epub 2022 Sep 20.

Development of New Drugs for Autoimmune Hemolytic Anemia.

Pharmaceutics. 2022 May 11;14(5):1035. doi: 10.3390/pharmaceutics14051035.

Bruton's Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives.

J Clin Med. 2022 May 16;11(10):2807. doi: 10.3390/jcm11102807.

Autoimmune Hemolytic Anemia in Chronic Lymphocytic Leukemia: A Comprehensive Review.

Cancers (Basel). 2021 Nov 19;13(22):5804. doi: 10.3390/cancers13225804.

本文引用的文献

Clinical response to ibrutinib is accompanied by normalization of the T-cell environment in CLL-related autoimmune cytopenia.

Leukemia. 2016 Nov;30(11):2232-2234. doi: 10.1038/leu.2016.157. Epub 2016 May 25.

Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib.

Haematologica. 2016 Jun;101(6):e254-8. doi: 10.3324/haematol.2015.138289. Epub 2016 Mar 24.

Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.

Leukemia. 2016 Feb;30(2):346-50. doi: 10.1038/leu.2015.273. Epub 2015 Oct 7.

Autoimmune haemolytic anaemia occurring during ibrutinib therapy for chronic lymphocytic leukaemia--response to Rider et al.

Br J Haematol. 2016 Apr;173(2):327-8. doi: 10.1111/bjh.13601. Epub 2015 Jul 20.

Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia.

Br J Haematol. 2015 Sep;170(5):734-6. doi: 10.1111/bjh.13328. Epub 2015 Feb 25.

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

N Engl J Med. 2014 Jul 17;371(3):213-23. doi: 10.1056/NEJMoa1400376. Epub 2014 May 31.

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Blood. 2013 Oct 10;122(15):2539-49. doi: 10.1182/blood-2013-06-507947. Epub 2013 Jul 25.

The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.

Arthritis Res Ther. 2011 Jul 13;13(4):R115. doi: 10.1186/ar3400.

Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment.

Br J Haematol. 2011 Jul;154(1):14-22. doi: 10.1111/j.1365-2141.2011.08707.x. Epub 2011 May 1.

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis.

Nat Chem Biol. 2011 Jan;7(1):41-50. doi: 10.1038/nchembio.481. Epub 2010 Nov 28.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献